Loading...
Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma
Traditionally, overall survival (os) has been considered the “gold standard” for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However, as the available options for continuing therapy in...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Multimed Inc.
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3176905/ https://ncbi.nlm.nih.gov/pubmed/21969807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|